CHANEL's investment focus is primarily on strategic areas that align with its luxury brand and sustainability commitments. This includes companies in Life Sciences Tech, Drug Molecular Modelling, and Fashion Tech, as well as climate change ventures and sustainable initiatives. Additionally, CHANEL invests in high-end watchmaking expertise and technology to enhance its boutique experience.
75% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals). Average disclosed round size is $71.0M (across 3 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 P2 Science Inc. | Unknown | — | Feb 2023 |
 Evolved By Nature | Series C | $120M | Jun 2022 |
 Arcaea | Series A | $78M | Oct 2021 |
| SSulapac | Series A | $15M | Dec 2019 |
Top Co-Investors
Mousse Partners2 shared
Viking Global1 shared
Givaudan1 shared
Wittington Ventures1 shared
Bonnier Ventures1 shared
Lifeline Ventures1 shared
Lewis & Clark AgriFood1 shared
Heritage Group1 shared
Ontario Teachers' Pension Plan1 shared
Senator Investment Group1 shared
Kraft Group1 shared
Emerald Development Managers1 shared
Last updated: 10 April 2026